Adaptive Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes for Specialized Environments

This inventive concept adapts the restimulation of cryopreserved tumor infiltrating lymphocytes for specific, narrow market or unique operational environments, addressing high-security needs, disaster relief, extreme weather conditions, and resource-constrained areas.

The original patent disclosed a method for restimulating cryopreserved tumor infiltrating lymphocytes, but it did not address the limitations and challenges of implementing this technology in specialized environments. This inventive concept solves the problem of adapting the restimulation process for unique operational environments, ensuring the effective treatment of bulky, refractory cancers in a variety of settings.

The inventive concept comprises four specialized variations of the restimulation method: 1) a secure, isolated environment for high-security needs; 2) a portable cryopreservation unit and restimulation protocol module for disaster relief; 3) a thermally insulated container and temperature-resistant bioreactor for extreme weather conditions; and 4) a low-power, portable thawing device and simplified cocktail of cytokines and growth factors for remote, resource-constrained areas. These variations ensure the effective restimulation of cryopreserved tumor infiltrating lymphocytes in diverse environments.

The new claims introduce novel and non-obvious adaptations of the restimulation method for specialized environments, including the use of secure, isolated environments, portable cryopreservation units, thermally insulated containers, and low-power, portable thawing devices. These adaptations provide a significant improvement over the original patent by enabling the effective treatment of bulky, refractory cancers in a variety of settings.

Other embodiments of the inventive concept could include adaptations for use in high-altitude or high-radiation environments, or for treating specific types of cancer. Additionally, the restimulation method could be integrated with other immunotherapies or cancer treatments to enhance its effectiveness.

The inventive concept has significant commercial potential in the fields of immunotherapy and cancer treatment, particularly in high-security, disaster relief, and resource-constrained settings. The market for this technology is expected to grow as the need for adaptable and effective cancer treatments increases.